---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-104004"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:23:36.365110+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics Q3 net loss $59.1M; lead drug regulatory update delayed to Q1 2026

## Summary
- Net loss of $59.1M ($0.85 per share) vs $50.8M ($0.74) in Q3 2024; R&D expenses up 21% to $58.4M.
- Cash $648.3M (down from $879.5M at Dec 2024); additional $38.2M R&D tax credit received Oct 2025; runway into 2028.
- Dose selection for zelenectide pevedotin Duravelo-2 trial and potential approval pathway update expected Q1 2026.
- Strengthened Board with appointments of Charles Swanton, Roger Dansey, and Hervé Hoppenot.
- BT5528 and BT7480 combination data presentations pushed to H1 2026; initial BRC EphA2 human imaging data expected H1 2026.

## SEC filing metadata
- accession: 0001104659-25-104004
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465925104004/0001104659-25-104004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465925104004/tm2529754d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-104004
- JSON: https://secwatch.observer/filing/0001104659-25-104004.json
- Plain text: https://secwatch.observer/filing/0001104659-25-104004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.